Pfizer's Essential Health Leadership On Why US Biosimilars Will Take Off – Eventually

 
• By Jessica Merrill

Essential Health Group President Angela Hwang, Biosimilars President Richard Blackburn and US Biosimilars General Manager John Kennedy discuss the early challenges Pfizer has faced with Inflectra and optimism for the US biosimilars market over the long term.

New York, July 19, 2016: Corporate lettering on the exterior of the Pfizer headquarters in Manhattan.

More from Strategy

More from Business